Hepatitis D Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Acute, Chronic), By Diagnosis (Blood Tests, Elastography, Liver Biopsy, Serologic Testing, Others), By Region & Competition, 2021-2031F

The Global Hepatitis D Market is projected to expand from USD 2.01 Billion in 2025 to USD 2.73 Billion by 2031, reflecting a compound annual growth rate of 5.24%. This sector involves the creation and sale of diagnostic assays and antiviral drugs specifically for managing Hepatitis D Virus (HDV), a satellite virus that depends on Hepatitis B for replication. Growth is primarily driven by the regulatory clearance of new entry inhibitors and an increased global emphasis on treating viral hepatitis co-infections to mitigate liver disease progression. As noted by the World Hepatitis Alliance, approximately 12 million individuals worldwide were living with hepatitis delta in 2025, constituting a significant patient base that urgently requires therapeutic solutions and fuels the demand for effective pharmaceutical treatments.

Conversely, market expansion faces a substantial hurdle due to limited diagnostic accessibility and low awareness, especially in resource-constrained regions where the disease is most common. The expense and technical demands of confirmatory HDV RNA testing frequently hinder the identification of eligible patients, thereby restricting the market reach of approved therapies. This gap in diagnostics creates a formidable obstacle to market penetration, leaving a vast majority of the infected population undiagnosed and without access to specialized medical care.

Market Driver

The authorization and launch of novel antiviral therapies act as the primary engine for the Global Hepatitis D Market, fundamentally transforming a treatment landscape that previously relied on off-label interferon protocols. The successful introduction and reimbursement of first-in-class entry inhibitors have proven the profitability of HDV-specific medications, boosting revenue for major pharmaceutical players. This success is highlighted by the strong performance of liver disease portfolios featuring these targeted treatments; for instance, Gilead Sciences reported in its First Quarter 2025 Financial Results that liver disease portfolio sales rose by 3% to $758 million, largely attributed to heightened demand for chronic hepatitis delta virus (HDV) and hepatitis B products.

Simultaneously, the market is strengthened by a solid clinical pipeline of entry inhibitors and immunomodulators, attracting significant late-stage investment and acquisition deals. Pharmaceutical firms are actively acquiring rights to promising assets, such as monoclonal antibodies, signaling long-term industry confidence. A prime example occurred in December 2025, when Mirum Pharmaceuticals announced its acquisition of Bluejay Therapeutics for an upfront payment of $620 million to obtain the late-stage antibody brelovitug. Despite these therapeutic strides, educational hurdles remain; the World Hepatitis Alliance's May 2025 'Hepatitis Delta Global Landscape Survey Report' indicated that 68.4% of community respondents cited a lack of general disease knowledge as the primary barrier to accessing testing and treatment.

Market Challenge

A persistent shortage of diagnostic accessibility severely impedes the Global Hepatitis D Market by limiting the number of identified patients eligible for therapy. The industry depends heavily on complex confirmatory RNA tests to verify active infections, yet these tools are often inaccessible or cost-prohibitive in areas with the highest infection rates. These technical and financial obstacles prevent healthcare providers from confirming cases, effectively disconnecting high disease prevalence from actual pharmaceutical demand. Without broad access to these diagnostics, pharmaceutical companies are unable to effectively reach high-need markets, leaving the majority of the target demographic undiagnosed and untreated.

This diagnostic bottleneck restricts the total addressable market by stalling patient identification at the fundamental level. As reported by the World Hepatitis Alliance in 2024, only 13% of individuals with chronic Hepatitis B were diagnosed globally. Because Hepatitis D is an obligate satellite virus that requires a confirmed Hepatitis B diagnosis for identification, this low primary detection rate inherently limits the potential growth of the Hepatitis D sector. The failure to capture this large segment of the infected population directly compromises the commercial viability of new antiviral therapies and constrains revenue generation.

Market Trends

The increase in strategic biopharmaceutical licensing and acquisitions is restructuring the market as companies aim to reduce development risks and establish commercial presence for late-stage assets. Distinct from the organic growth of approved drugs, this trend involves high-value exclusive deals that confirm the potential of combination therapies, especially those merging RNA interference with monoclonal antibodies. Such collaboration is crucial for accessing regional markets and managing the intricate regulations of orphan drug indications. For example, Pharmabiz.com reported in December 2025 that Vir Biotechnology received an initial EUR 55 million payment from Norgine for exclusive European rights to its investigational RNAi and antibody combination, highlighting the significant value placed on advanced pipeline candidates.

The sector is also shifting toward patient-centric oral interventions through the emergence of novel viral entry inhibitor therapies, addressing the administration challenges of earlier injectable treatments. While current standards depend on daily subcutaneous injections, the industry is heavily investing in orally bioavailable small molecules that block viral entry via the sodium taurocholate cotransporting polypeptide (NTCP). This evolution seeks to improve long-term adherence and widen treatment availability in community settings. Reflecting this investment, Assembly Biosciences reported in its 'Year End 2024 Financial Results' in March 2025 that collaborative revenues reached $28.5 million, driven largely by milestone payments for its next-generation oral antiviral pipeline.

Key Market Players

• F. Hoffmann-La Roche Ltd
• NanoGen Healthcare Pvt. Ltd.
• PROBIOMED SA de CV
• 3SBio Group
• Hepion Pharmaceuticals, Inc.
• Antios Therapeutics, Inc.
• PharmaEssentia Corporation
• Replicor
• Apotex Corp.
• Mylan N.V
• Aurobindo Pharma Limited

Report Scope

In this report, the Global Hepatitis D Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hepatitis D Market, By Type

• Acute
• Chronic

Hepatitis D Market, By Diagnosis

• Blood Tests
• Elastography
• Liver Biopsy
• Serologic Testing
• Others

Hepatitis D Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hepatitis D Market.

Available Customizations:

Global Hepatitis D Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).